This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

GISSI-2 trial

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

20891 patients who were admitted to hospital within 6 hr of the onset of symptoms of acute myocardial infarction were randomised to:

Thrombolysis:

  • streptokinase (1.5 MU over 30-50 min)
  • t-PA (100 mg over 3 hr)

Anticoagulation:

  • aspirin daily for 30 days (325 mg)
  • aspirin daily for 30 days plus subcutaneous heparin (12500 IU subcutaneous twice daily)

There were no significant differences in the 35 day mortality rates between:

  • streptokinase and t-PA
  • aspirin and aspirin+heparin

There was a small, but significant, increased incidence of stroke associated with t-PA.

Reference:

  • Gruppo Italiano per lo Studio dell Streptochinasi nell' Infarcto Miocardico (GISSI). GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. (1990). Lancet, 336, 65-71.
  • In hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. (1990). Lancet, 335, 71-5.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.